MentionFox
Home › funding signals › Cantai Therapeutics, Inc.
Form D · on the record

Cantai Therapeutics — $3M Form D filing, January 2026

Before you sell to, join or invest in Cantai Therapeutics, Inc.

MentionFox check on Cantai Therapeutics, Inc.: only 1 source on file so far (checked 7 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/cantai-therapeutics-inc-form-d-26000001

Check Cantai Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Cantai Therapeutics, Inc.?

Cantai Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-21.

Cantai Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 21, 2026. The filing reports $3M sold. Its industry group is Biotechnology. It names Ross Leimberg (Executive Officer, Director), Errik Anderson (Executive Officer), Getta Vemuri (Executive Officer, Director) (SEC Form D, January 21, 2026).

125 companies raised this week.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

Andersen Aggregator LLC$1.9BBusiness services
AT Umbrella LLC$1.9BBusiness services
Legora, Inc.$221MAI and software
MD INVESTMENT LLC$169MBusiness services
Serval Inc.$149MAI and software
Check one company free

5 more Biotechnology raises in Pennsylvania within 90 days ↓

Is this your company?

Key facts

Run the free check on Cantai Therapeutics, Inc. →

Sell to companies like Cantai Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Cantai Therapeutics, Inc.

New Form D on file · 2026-01-21 · the record

$3M
raise on the record
D
filing
3
investors in
PENNSYLVANIA
based
Open the record →

What the record says

FilingForm D
Filed2026-01-21
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
Year formed2023
BasedPHILADELPIA, PENNSYLVANIA
CIK1991732
Accession0001991732-26-000001

Pitching, partnering or investing alongside them? See who really runs and owns Cantai Therapeutics, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Cantai Therapeutics, Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.

What do you want to do with Cantai Therapeutics, Inc.?

Get the full cited report on Cantai Therapeutics, Inc.

What the filing shows about Cantai Therapeutics, Inc.

  • 3 investors had already put money in when it filed.
  • The filing names 3 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Cantai Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Who the filing names, and in what role

The filing gives Cantai Therapeutics, Inc.'s address as 3675 Market Street, Suite 200, Philadelpia, PA 19104.

Keep digging

Who else raised the same week in biotechnology

What the filing says

  • Offered: $3,000,000. Sold: $3,000,000. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 3 had already invested. (filing)
  • Date of first sale: January 15, 2026. (filing)
  • Types of securities: Equity. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters (marked as an estimate). (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Cantai Therapeutics, Inc. See pricing

Is Cantai Therapeutics, Inc. a real, registered company?

Cantai Therapeutics, Inc. is a registered filer with the SEC (CIK 1991732) and has filed since 2023-11-20. 4 filings are on record, the latest on 2026-01-21.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Cantai Therapeutics, Inc.?

Cantai Therapeutics, Inc.'s Form D of 2026-01-21 names Ross Leimberg, Errik Anderson and Getta Vemuri as its officers, directors or promoters.

How much has Cantai Therapeutics, Inc. raised?

Its new offerings report $4.25M sold across 3 offerings, as its own filings state.

Filing history · 4 filings on this registrant
Form D/A, amended · 2023-11-20 · $700KForm D · 2023-11-20 · $700KForm D · 2025-07-15 · $550KForm D · 2026-01-21 · $3M · this page 2023-11-20 2026-01-21

A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $3M, filed week of Jan 19

Trailing twelve months. 763 filings in Biotechnology, totalled by week. The dot is this raise, $3M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Cantai Therapeutics, Inc.?

What the filing shows about Cantai Therapeutics, Inc.

  • 3 investors had already put money in when it filed.
  • The filing names 3 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Cantai Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Cantai Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Cantai Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Cantai Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

On these startup lists

Biotech startups

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

Cantai Therapeutics, Inc.: Raised $3M, Form D filed 2026-01-21
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/cantai-therapeutics-inc-form-d-26000001
Last updated 2026-11-07
Primary record: SEC filing 1 · SEC filing 2
Cantai Therapeutics raised $3M — SEC Form D filing, January 2026. MentionFox, 2026-11-07. https://mentionfox.com/funding/cantai-therapeutics-inc-form-d-26000001